Company Overview

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and biologic treatments targeting innate immune system dysfunction associated with cancer, neurodegenerative diseases, and chronic inflammation. The company operates within the biotechnology and biopharmaceutical industries, with research programs centered on modulating immune responses through proprietary platforms designed to selectively target pathological inflammatory pathways while preserving normal immune function. Public filings and company disclosures identify its primary development areas as oncology, Alzheimer’s disease, and regenerative medicine.

The company’s principal business lines are built around three technology platforms: DN-TNF, INKmune, and XPro-related therapeutic programs. These platforms are intended to address diseases where chronic inflammation or impaired immune surveillance contributes to disease progression. INmune Bio’s lead assets include therapies aimed at reducing neuroinflammation in Alzheimer’s disease and activating natural killer (NK) cells for cancer treatment. The company was founded in 2015 and is headquartered in the United States. Since inception, it has evolved from an early-stage immunology research company into a multi-platform clinical-stage biotechnology developer pursuing multiple investigational therapies across distinct therapeutic categories.

Business Operations

INmune Bio organizes its operations around several core therapeutic platforms. The DN-TNF platform focuses on selectively neutralizing soluble tumor necrosis factor (TNF), a cytokine associated with chronic inflammation and neurodegenerative disease progression. The company’s XPro program, including XPro1595, has been evaluated in clinical studies targeting neuroinflammatory mechanisms associated with Alzheimer’s disease. The INKmune platform is designed to prime patient NK cells to recognize and destroy tumor cells, primarily in oncology indications. The company also maintains regenerative medicine-related initiatives associated with immune modulation and cellular repair processes.

Revenue generation has historically been limited because INmune Bio remains a clinical-stage company without approved commercial products as of publicly available filings. Operations are funded primarily through equity offerings, strategic financing activities, and capital markets transactions disclosed in SEC filings. The company conducts clinical and research activities in the United States while collaborating with contract research organizations, academic institutions, and manufacturing partners supporting therapeutic development and clinical trial execution. Publicly available disclosures indicate the company relies extensively on proprietary intellectual property, biologic development capabilities, and clinical partnerships to advance its pipeline.

Strategic Position & Investments

INmune Bio’s strategic direction centers on advancing targeted immune-modulating therapies that address inflammatory drivers in cancer and neurodegenerative disease. The company has emphasized precision immunology approaches intended to selectively inhibit harmful inflammatory signaling while preserving beneficial immune activity. Its development strategy includes advancing mid-stage and early-stage clinical trials, expanding biomarker-driven patient selection, and pursuing indications with substantial unmet medical need. Management presentations and regulatory filings identify Alzheimer’s disease and oncology immunotherapy as key long-term growth priorities.

The company has invested substantially in clinical development programs tied to the XPro1595 and INKmune platforms. Public disclosures also reference collaborations with research institutions and external manufacturing organizations supporting development and scaling activities. INmune Bio’s competitive positioning is tied to its differentiated approach to soluble TNF inhibition and NK-cell priming technologies, which management states may provide advantages over broader immunosuppressive approaches. While the company has discussed future partnership opportunities and broader platform applicability, some long-term commercialization outcomes remain dependent on clinical trial success and regulatory review. Data regarding future commercial partnerships or acquisition activity remains inconclusive based on available public sources.

Geographic Footprint

INmune Bio is headquartered in Boca Raton, Florida, with primary operational and clinical activities concentrated in the United States. The company’s clinical development efforts involve trial sites and research collaborations that extend into additional regions depending on study requirements and regulatory approvals. Public filings and investor materials indicate the company maintains an international outlook for future commercialization opportunities, particularly in large pharmaceutical markets addressing neurodegenerative disease and oncology.

The company’s market presence is primarily tied to the North American biotechnology sector, though its therapeutic focus areas have potential relevance across North America, Europe, and selected international healthcare markets. Clinical and manufacturing partnerships may involve organizations operating globally, particularly for biologics production and trial support. However, as of currently available public disclosures, INmune Bio does not report broad commercial operating infrastructure outside the United States because it has not yet launched approved products commercially.

Leadership & Governance

INmune Bio was co-founded by R. Jeffrey Meckler and scientific collaborators involved in immunology and inflammation research. Leadership has consistently emphasized the development of therapies targeting innate immune dysfunction as a foundational strategy for treating diseases associated with chronic inflammation. The company’s governance framework reflects a biotechnology development model focused on scientific advisory expertise, clinical advancement, and capital allocation toward pipeline progression.

Key executives and leadership figures include:

• R. Jeffrey Meckler – Chief Executive Officer
• David Moss – Chief Financial Officer
• RJ Tesi, M.D. – Chief Medical Officer
• Mark Lowdell, Ph.D. – Chief Scientific Officer
• Mitchell Glass, M.D. – Executive leadership role associated with clinical development and neuroscience strategy

Management communications and investor materials indicate leadership is focused on advancing differentiated immunotherapy platforms through clinical validation, regulatory engagement, and strategic development partnerships. Executive strategy has consistently highlighted the company’s objective of addressing inflammatory mechanisms underlying major chronic diseases through selective immune modulation technologies.